Dyne Therapeutics (DYN) Change in Accured Expenses (2019 - 2026)

Dyne Therapeutics (DYN) has reported Change in Accured Expenses for 8 consecutive years, with $19.0 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Change in Accured Expenses rose 141.72% year-over-year to $19.0 million; the TTM figure through Jun 2026 stood at $23.2 million (up 98.56% YoY), while the FY2025 annual figure was $8.3 million, up 192.14% from the prior year.
• Change in Accured Expenses improved to $19.0 million in Q2 2026 per DYN's latest filing, from -$4.8 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $21.4 million in Q4 2023 and bottomed at -$28.8 million in Q1 2024.
• Historically, Change in Accured Expenses has averaged $2.0 million across 5 years, with a median of $276500.0 in 2022.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses soared 917.29% — and 2025, when it slumped 854.89%.
• Dyne Therapeutics' Change in Accured Expenses stood at $4.6 million in 2022, then jumped by 360.85% to $21.4 million in 2023, then tumbled by 104.63% to -$991000.0 in 2024, then plunged by 854.89% to -$9.5 million in 2025, then soared by 300.39% to $19.0 million in 2026.
• Business Quant data shows DYN's Change in Accured Expenses at $19.0 million in Q2 2026, -$4.8 million in Q1 2026, and -$9.5 million in Q4 2025.